Dow Wolff Cellulosics

Dow Chemical Company creates Dow Wolff Cellulosics, a $1 bil. specialty business unit that sells high-performance cellulosics for personal care and other applications, firm announces July 2. The new business unit combines all activities and interests of two previously established companies - Wolff Walsrode AG and Dow Chemical's Water Soluble Polymers business. The new unit sells cellulosics such as SoftCAT SX Polymers, which figure in hair care, Methocel cellulose ethers, which are used in skin care, and Polyox water-soluble resins, which are an important component of skin cleansers, oral care, hair care and shaving products. The new unit will be led by Martin Sonntag as general manager. Steve Swartzmiller will serve as director of global innovation and R&D, Reiner Roghmann as global manufacturing director, and Volker Eckhardt as head of the firm's methyl cellulosics business manufacturing, firm says...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from HBW Insight

Gardenia Blue, OrangeOvation, StellarYellow Latest Natural Pivots In US Food Color Market

 
• By 

FDA’s fourth approval in past two months for color derived from natural sources to use in foods is Gardenia Blue Interest Group’s color additive petition for gardenia blue. Lycored launches StellarYellow and C Clear as alternatives for synthetic dyes yellow Nos. 5 and 6 and OrangeOvation C Clear for

Stada Acquires Fortacell To Grow In Balkans

 
• By 

Stada's Serbian subsidiary Hemofarm has enhanced its offering in the dietary supplements category with the acquisition of Fortacell from Goodwill Pharma.

House Health Subcommittee Members Agree OMUFA Crucial, Split On FDA Staff Cuts’ Impact

 
• By 

Subcommittee members aren’t on same page about whether FDA staff cuts ordered by the Trump administration will prevent the agency from fulfilling its responsibilities for the OTC drug sector.